Linagliptin: A Novel Xanthine-Based Dipeptidyl Peptidase-4 Inhibitor for Treatment of Type II Diabetes Mellitus

E-ISSN： 1875-6417|7|5|325-335

ISSN： 1573-3998

Source： Current Diabetes Reviews, Vol.7, Iss.5, 2011-09, pp. : 325-335

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical overview of linagliptin, a dipeptidyl peptidase-4 inhibitor, in patients with Type 2 diabetes mellitus

By Forst Thomas Pfützner Andreas

Expert Review of Endocrinology and Metabolism, Vol. 8, Iss. 1, 2013-01 ,pp. : 21-35

Informa Healthcare

Access to resources Recommend Favorite

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus

By Raz I. Hanefeld M. Xu L. Caria C. Williams-Herman D. Khatami H.

Diabetologia, Vol. 49, Iss. 11, 2006-11 ,pp. : 2564-2571

Springer Publishing Company

Access to resources Recommend Favorite

Acute onset of rheumatoid arthritis associated with administration of a dipeptidyl peptidase-4 (DPP-4) inhibitor to patients with diabetes mellitus

By Sasaki Takashi

Diabetology International, Vol. 1, Iss. 2, 2010-12 ,pp. : 90-92

Springer Publishing Company

Access to resources Recommend Favorite

Alogliptin: a Novel Molecule for Improving Glycemic Control in Type II Diabetes Mellitus

Current Diabetes Reviews, Vol. 6, Iss. 6, 2010-11 ,pp. : 410-421

Bentham Science Publishers

Access to resources Recommend Favorite

An Update in Incretin-Based Therapy: A Focus on Dipeptidyl Peptidase - 4 Inhibitors

Current Diabetes Reviews, Vol. 8, Iss. 3, 2012-05 ,pp. : 169-182

Bentham Science Publishers

Access to resources Recommend Favorite